Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Philips and Merck partner to advance personalized fertility treatment
Royal PhilipsJanuary 14, 2021 GMT
January 14, 2021
Remote patient monitoring, cloud-based platform services and mobile, AI-enabled ultrasound diagnostics to support improved access to care and better outcomes in fertility treatment
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a multi-year partnership with Merck, a leading science and technology company, to develop clinical-grade digital solutions for highly personalized fertility treatment. Leveraging digital health technologies, advanced informatics and mobile, AI-enabled ultrasound diagnostics, these solutions will aim to better inform patients and clinicians about the choice and timing of fertility treatment to maximize the chances of conception.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Alexion Provides Update on Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19
January 13, 2021 GMT
BOSTON (BUSINESS WIRE) Jan 13, 2021
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the decision to pause further enrollment in the global Phase 3 study of ULTOMIRIS ® (ravulizumab-cwvz) in adults with severe COVID-19 requiring mechanical ventilation. This decision is based on the recommendation of an independent data monitoring committee (IDMC), following their review of data from a pre-specified interim analysis. The IDMC recommended that additional enrollment be paused, pending further analysis of the data, due to lack of efficacy when ULTOMIRIS was added to best supportive care, compared to best supportive care alone. There were no new safety findings observed. The study will continue for patients already enrolled, including compl
Press release content from Business Wire. The AP news staff was not involved in its creation.
Global Maternity Wear Market (2020 to 2025) - Featuring Seraphine, Asos and H&M Among Others - ResearchAndMarkets.com
January 8, 2021 GMT
DUBLIN (BUSINESS WIRE) Jan 8, 2021
The global maternity wear market size is anticipated to grow at a CAGR of 4.71% to reach US$13.742 billion in 2025 from US$10.426 billion in 2019. Pregnancy fashion and rising number of pregnant women within the working population in developing nations are the elements expected to drive the demand for the product over this period.
ADVERTISEMENT
Earlier, the utilization of maternity wear was only for hiding baby bump without thinking about its fitting. These days, women are highly conscious about the fitting of the garments they wear. Fashion and design awareness are increasing among the modern mothers. This factor is expected to drive the demand for the outerwear section during the forecast period. Besides, the fab